May 2015 Briefing – Pharmacy
Here are what the editors at HealthDay consider to be the most important developments in Pharmacy for May 2015. This roundup includes the latest...
Physician Intervention Doesn’t Cut Maternal Vaccine Hesitancy
Second study shows high PBE schools colocated with schools with elevated PME rates
Weight-Based Enoxoparin Dosing Best for Obese After C-Section
Weight-based dosing more effective than BMI-based dosing for venous thromboembolism prophylaxis
Celecoxib Safe, Effective for Brucellosis-Associated Depression
Greater response to treatment in celecoxib versus placebo group at study end
FDA Approves Rapamune for Lymphangioleiomyomatosis
Rare, progressive lung disease affects mostly women of child-bearing age
Greater Benefit for Early Antiretroviral Tx Initiation in HIV
NIH-funded trial results appear likely to impact global treatment guidelines
ASCO: PD-1 Immunotherapy Benefits Patients With NSCLC
Fewer side effects, longer survival for nivolumab versus docetaxel
Primary Androgen Deprivation Tx May Raise DM Risk by 60 Percent
Findings among men treated for localized prostate cancer
FDA: Two Drugs Approved for Irritable Bowel Syndrome
U.S. Food and Drug Administration approves Viberzi (eluxadoline) and Xifaxan (rifaximin)
Metformin Linked With Lower Open-Angle Glaucoma Risk
Study found people with highest dose were 25 percent less likely to develop condition
